Enrofloxacin Market - Size, Share, Outlook, and
Opportunity Analysis, 2019 – 2027
The global enrofloxacin market size is expected to witness potential gains in the future, and
register a significant CAGR over the forecast period (2019 – 2027).
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2742
Market Overview
Enrofloxacin (ENR) is a fluoroquinolone antibiotic and a veterinary antibacterial agent. It is sold
under the trade name Baytril by the Bayer Corporation. ENR is currently approved for
treatment of individual pets and domestic animals in the U.S. by the U.S. Food and Drug
Administration (FDA). ENR is effective against a several gram-positive and gram-negative
bacteria such as Pseudomonas aeruginosa, Klebsiella, and E.coli. It is used for the treatment of
infections of skin and soft tissue, urinary tract infections in dogs and cats, Chlamydophila felis
infections in cats, and ulcerative colitis caused by Escherichia coli in dogs. Significant growth in
the poultry sector is expected to have positive impact on the market growth of enrofloxacin
over the forecast period.
Market Dynamics
Increasing use of ENR in treatment of infections caused by both Gram-negative and Gram-
positive bacteria is expected to boost the market growth. ENR is administered to cattle by
subcutaneous injection and to pigs by intramuscular injection. It is administered orally to cattle,
pigs, turkey, and chickens, for the treatment of infections of the respiratory and alimentary
tract.
However, in rare instances, use of ENR in cats has been linked with retinal toxicity. The drug
cannot be used in pets that are allergic to it. ENR is also associated with some side effects such
as vomiting, diarrhea, and lack of appetite. Moreover, effective in September 2005, enrofloxacin
was withdrawn from use in the U.S. poultry farms. These factors are expected to hinder growth
of the enrofloxacin market over the forecast period.